Patents Assigned to Inserm
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20160346406
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: William ROSTENE, Christophe BAUDOUIN, David GODEFROY, Alexandre DENOYER
  • Oligonucleotides and Methods for Inhibiting or Reducing Bacterial Biofilms
    Publication number: 20160348102
    Abstract: The present invention relates to oligonucleotides useful for inhibiting or reducing bacterial biofilms.
    Type: Application
    Filed: January 29, 2015
    Publication date: December 1, 2016
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE RENNES 1
    Inventors: Brice Felden, Valerie Bordeau
  • DIAGNOSIS OF HEREDITARY SPASTIC PARAPLEGIAS (HSP) BY DETECTION OF A MUTATION IN THE KIAA1840 GENE OR PROTEIN
    Publication number: 20160348172
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Application
    Filed: March 12, 2014
    Publication date: December 1, 2016
    Applicant: Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: Hamid AZZEDINE, Alexis BRICE, Giovanni STEVANIN, Filippo SANTORELLI, Paola DENORA
  • Methods for treating myocardial infarction comprising administering sonic hedgehog
    Patent number: 9504732
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 29, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20160331818
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 17, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc LOPEZ, Daniel OLIVE
  • WATER SOLUBLE 4-AZAPODOPHYLLOTOXIN ANALOGS
    Publication number: 20160333022
    Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
    Inventors: Guy CHABOT, Sylviane GIORGI-RENAULT, Stéphanie DESBENE-FINCK, Philippe HELISSEY, Raphaël LABRUERE, Marléne TESTUD, Daniel SCHERMAN
  • IL-15 mutants having antagonist activity
    Patent number: 9493533
    Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLII68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: November 15, 2016
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Jérôme Bernard, Ariane Plet, Yannick Jacques, Catherine Harb, Agnès Quemener, Erwan Mortier
  • Production of a human beta cell line from an early post natal pancreas
    Patent number: 9493743
    Abstract: The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non-foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing to generate human Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation. They have a gene expression profile that resembles to adult beta cells. In addition, the human beta cell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignees: UNIVERCELL BIOSOLUTIONS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Paul Czernichow, Philippe Ravassard, Raphael Scharfmann
  • Method for diagnosing a hemoglobin-related disorder
    Patent number: 9494603
    Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 15, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud, Assistance Publique—Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
    Inventors: Veronique Baudin-Creuza, Corinne Vasseur, Frederic Galacteros
  • Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
    Patent number: 9494599
    Abstract: The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41?), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: November 15, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT (PARIS VII), UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger, Dominique-Charles Valla
  • APTAMERS INHIBITING THE ENZYMATIC ACTIVITY OF THE MMP-9 PROTEIN
    Publication number: 20160326530
    Abstract: The invention relates to an aptamer that has a G-quadruplex structure and is able to inhibit the enzymatic activity of the MMP-9 protein, as well as to the dermatological and cosmetic uses thereof.
    Type: Application
    Filed: December 30, 2014
    Publication date: November 10, 2016
    Applicants: L V M H Recherche, Institut National De La Santé Et De La Recherche Médicale (INSERM)
    Inventors: Eric Dausse, Jean-Jacques Toulme, Jean Hubert Cauchard, Robin Kurfurst, Sylvianne Schnebert
  • METHODS FOR ADHERING TISSUE SURFACES AND MATERIALS AND BIOMEDICAL USES THEREOF
    Publication number: 20160325010
    Abstract: The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.
    Type: Application
    Filed: December 10, 2014
    Publication date: November 10, 2016
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Ludwik LIEBLER, Anne MEDDAHIPELLE, Didier LETOURNEUR
  • Methods for the treatment of leber congenital amaurosis
    Patent number: 9487782
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 8, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Methods for cancer management targeting Co-029
    Patent number: 9487586
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: November 8, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • Methods for treating pancreatic cancer
    Patent number: 9487582
    Abstract: The present disclosure is directed to methods of treating pancreatic cancer in subject using cancer with antibodies that specifically bind to progastrin.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: November 8, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS), LES LABORATORIES SERVIER
    Inventors: Leïla Houhou, Dominique Joubert, Frédéric Hollande
  • TET2 AS A DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS
    Publication number: 20160319370
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
    Type: Application
    Filed: June 8, 2016
    Publication date: November 3, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS-SUD
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • COMBINATION OF BEZAFIBRATE AND OF RESVERATROL OR RESVERATROL DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING A MITOCHONDRIAL ENERGY DYSFUNCTION
    Publication number: 20160317483
    Abstract: The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both bezafibrate and resveratrol or resveratrol derivatives. The combination is more particularly used in the treatment of moderate defects of ?-oxidation of long-chain fatty acids or of the respiratory chain of mitochondria.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicants: Institut National De La Santé Et De La Recherche Médicale (INSERM), Universite Paris Descartes
    Inventors: Jean Bastin, Fatima Djouadi
  • Methods for determining developmental stage of human cumulus cells
    Patent number: 9481863
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: November 1, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER 1
    Inventor: Samir Hamamah
  • Method for rejuvenating cells
    Patent number: 9476031
    Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: October 25, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER I, UNIVERSITE MONTPELLIER II
    Inventors: Alexandre Prieur, Ollivier Milhavet, Jean-Marc Lemaitre, Laure Lapasset
  • Melanoma antigen peptide and uses thereof
    Patent number: 9475841
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 25, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel